Search Results

DCGI Highlights India's Contributions to Global Healthcare; Pharmaceutical Industry's Future Directions

Glenmark Launches DCGI-Approved Brukinsa to Transform Blood Cancer Treatment in India

Batch-specific recall of painkillers, antifungals, and diabetes drugs; spurious products traced to unauthorized manufacturers

New code may have some implications for the pharmaceutical companies but would benefit consumers

The Drug Controller General of India has asked state and Union Territory regulators to withdraw AstraZeneca's cancer drug Olaparib

To manufacture a generic drug, the manufacturer should follow Good Manufacturing Practices, use approved facilities and equipment, and prove bioequivalence to the branded drug